CURRENT VENTURES
Active Investments Supporting Lasting Innovation
Explore private companies within the portfolio. These holdings involve investments in businesses across various industries, offering a view of enterprises that may support value in the private equity portfolio.
COSTA RICA
HEALTHCARE
International Hospital Corporation (IHC)
Founded in 1991, International Hospital Corporation (IHC) develops, acquires, and operates hospitals in Latin America. Its first hospital opened in Hermosillo, Mexico, in 1996, and by 2004 the company had developed or acquired eight facilities across Mexico, Brazil, and Costa Rica. In 2006, the three affiliated hospital companies were consolidated into a single enterprise, at the time one of the largest pan-Latin American private hospital companies, with affiliations to U.S. institutions and international accreditations. IHC divested its Mexico division in 2013, sold its remaining Mexican asset in 2017, and exited Brazil in 2018. Today it operates Hospital CIMA San José in Costa Rica, accredited by the Joint Commission International six consecutive times, and is evaluating expansion in the United States and other markets. The company is transitioning from the "sick care" focus of traditional hospitals to a "health + care" model that extends patient access to wellness, preventive care, and functional medicine.
AUSTIN, TEXAS
DIAGNOSTICS & LIFE SCIENCES
Pattern Bioscience
Pattern Bioscience is an in vitro diagnostics company founded in 2016 to address antibiotic resistance. It developed a clinical microbiology platform using phenotypic single-cell technology and AI machine learning to identify pathogens in sterile and non-sterile samples and determine antibiotic susceptibility from patient samples, providing results faster than traditional methods. The investment thesis is technology that is clinically better, less expensive and significantly faster diagnostic and therapeutic pathways than current best practices.
RALEIGH, NORTH CAROLINA
ARTIFICIAL INTELLIGENCE
Pryon
Pryon is an artificial intelligence company focused on enterprise knowledge management and retrieval-augmented generation. Founded by developers of technologies for voice assistants, it creates a platform that processes unstructured content across formats to enable access to information, workflow automation, and decision-making, with applications in sectors like automotive, financial services, manufacturing, insurance, healthcare, telecom, energy, and government. The investment thesis is exposure to the AI market via “pick and shovel” type components for AI applications versus just large language models such as ChatGPT, Claude, Gemini, etc.
PALO ALTO, CALIFORNIA
BIOTECHNOLOGY
Transcripta Bio
Transcripta is a biotechnology company that combines experimental biology with artificial intelligence for drug discovery. Its platform builds a transcriptomic perturbation atlas by screening small molecules across genes, training AI models to predict drug effects and identify therapeutic candidates for various diseases, including rare disorders. It collaborates with biopharma companies, tech firms, and patient foundations to advance therapies. The investment thesis is exposure to the revolutionary capabilities of AI in the field of drug development.
BROOKLYN, NEW YORK
ARTIFICIAL INTELLIGENCE
Reflection AI
Reflection AI is an artificial intelligence company founded in 2024 by former Google DeepMind researchers to build frontier open-weight foundation models, combining large-scale pre-training with advanced reinforcement learning. The company positions itself as a U.S.-based open alternative to closed labs such as OpenAI and Anthropic, with a commercial focus on "sovereign AI" deployments for enterprises and governments that require transparent and customizable models. The investment thesis is exposure to a domestically-based open frontier model provider, offering differentiated positioning versus closed-model incumbents amid growing enterprise and sovereign demand for independently controllable AI infrastructure.
DIVERSIFIED INVESTMENT STRUCTURES
Special Purpose Limited Partnerships
Special Limited Partnerships (SLPs) allow accredited and qualified investors with smaller capital commitments to participate in private equity opportunities. These vehicles, such as Concorde Capital Energy Partners II, L.P. (CCEP II), pool allocations to access third-party funds, often taking passive positions. Investments target themes like energy royalties and may include equity, debt, or partnership interests in sectors such as oil and natural gas exploration, livestock, toys, manufacturing, hotel operations, information technology, commodities, and precious metals.
INTERESTED INVESTORS
Connect on Private Investments
Whether you are evaluating a current Concorde venture, exploring a private capital idea of your own, or simply seeking informed perspective on the private markets — we welcome the conversation. Share a few details and a member of our team will be in touch.
